Immuno-Oncology 360°

The 8th Annual Immuno-Oncology 360° Delivers Three Key Benefits:

- Access to KOLs driving the science
- Partnership opportunities with all stakeholders in Immuno-Oncology
- Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology

2022 Key Topic Areas
- Discovery/Preclinical Science
- Cell and Gene Therapy
- Translational Science
- Bispecifics
- Clinical Developments
- Neoadjuvant/Adjuvant Data
- Emerging Biomarkers
- Cytokines
- Clinical Operations
- IO Combinations
- Imaging Advancements
- Business Developments

Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:
- Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
- Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
- Partner to expand technology platforms to develop therapeutics at an accelerated rate
- Receive the latest pre-clinical, translational and clinical data from academia and industry
- Create and prioritize strategies targeted toward specific tumor types
- Identify and gain a greater understanding of what assets are available for potential combinations
- Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
- Get key investor and analyst evaluations and insights on the IO landscape, challenges and what's next
- Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
- Obtain coverage on a wide range of emerging technologies